These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32202061)

  • 21. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.
    Floyd JS; Wiggins KL; Sitlani CM; Flory JH; Dublin S; Smith NL; Heckbert SR; Psaty BM
    Diabetes Obes Metab; 2015 Dec; 17(12):1194-7. PubMed ID: 26179389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapsed 6q24-related transient neonatal diabetes mellitus successfully treated with sulfonylurea.
    Fu JL; Wang T; Xiao XH
    Chin Med J (Engl); 2019 Apr; 132(7):846-848. PubMed ID: 30897598
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of sulfanilamide preparations on the blood coagulation system in patients with diabetes mellitus].
    Vasiukova EA; Pisarskaia IV; Sharova IuA
    Ter Arkh; 1974; 46(10):53-5. PubMed ID: 4432223
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral hypoglycaemic agents.
    Borthwick LJ; Stowers JM
    Practitioner; 1979 Mar; 222(1329):358-66. PubMed ID: 450836
    [No Abstract]   [Full Text] [Related]  

  • 25. Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
    Simpson SH; Lee J; Choi S; Vandermeer B; Abdelmoneim AS; Featherstone TR
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):43-51. PubMed ID: 25466239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral hypoglycemic agents.
    Ferner RE
    Med Clin North Am; 1988 Nov; 72(6):1323-35. PubMed ID: 3054355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy of diabetes in adults using Glibornurid. Results and clinical studies].
    Schöffling K; Mehnert H; Ewald W; Haupt E; Wicklmayr M; Beyer J; Nemeth N
    Dtsch Med Wochenschr; 1973 May; 98(18):915-9. PubMed ID: 4633717
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of diabetes mellitus with glibornurid].
    Vignati E; Liuzzi A; Chiodini PG
    Minerva Med; 1973 Oct; 64(75):3900-6. PubMed ID: 4767761
    [No Abstract]   [Full Text] [Related]  

  • 29. Controlling diabetes with diet and oral hypoglycemic agents.
    Faludi G
    Geriatrics; 1976 Oct; 31(10):67-70. PubMed ID: 964602
    [No Abstract]   [Full Text] [Related]  

  • 30. [Oral antidiabetics].
    Bäbler M
    Schweiz Rundsch Med Prax; 1972 Feb; 61(8):242-6. PubMed ID: 4659095
    [No Abstract]   [Full Text] [Related]  

  • 31. [Long term efficacy and tolerance of antidiabetic treatments. New data].
    Mirouze J
    Nouv Presse Med; 1974 Jun; 3(24):1551-4. PubMed ID: 4211493
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical experience with the blood sugar reducing sulfonamide derivative glisoxepide].
    Petzoldt R; Riedesel G; Ramrath M; Grabs V; Haupt E; Schwedes U; Ewald W; Beyer J; Schöffling K
    Arzneimittelforschung; 1974 Mar; 24(0):429-32. PubMed ID: 4603399
    [No Abstract]   [Full Text] [Related]  

  • 33. A controlled clinical trial of a new oral hypoglycemic agent, glipizide (K 4024).
    Lentini S; Bossini A; Pirola LC
    Arzneimittelforschung; 1972 Jul; 22(7):1169-73. PubMed ID: 4678124
    [No Abstract]   [Full Text] [Related]  

  • 34. Sulfonylureas.
    Zimmerman BR
    Endocrinol Metab Clin North Am; 1997 Sep; 26(3):511-22. PubMed ID: 9314012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of hypoglycemic sulphonylureas in arrhythmias contributing to the mortality in acute myocardial ischemia.
    Koltai MZ; Aranyi Z; Ballagi-Podány G; Pogátsa G
    Acta Physiol Hung; 1990; 75 Suppl():175-6. PubMed ID: 2371854
    [No Abstract]   [Full Text] [Related]  

  • 36. Oral hypoglycaemic drugs: clinical pharmacology and therapeutic use.
    Stowers JM; Borthwick LJ
    Drugs; 1977 Jul; 14(1):41-56. PubMed ID: 328260
    [No Abstract]   [Full Text] [Related]  

  • 37. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Fasching P
    Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
    Scheen AJ
    Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetes and coronary artery disease: time to stop taking the tablets.
    Edwards RJ; Rakhit RD; Marber MS
    Heart; 1999 Jun; 81(6):674. PubMed ID: 10979714
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.